Intrahepatic Clear Cell Cholangiocarcinoma - An Uncommon Histologic Subtype: Case Report and Literature Review by Raimundo Fernandes, S et al.
1130-0108/2017/109/5/382-385
Revista española de enfeRmedades digestivas
© Copyright 2017. sepd y © ARÁN EDICIONES, S.L.
Rev esp enfeRm dig
2017, Vol. 109, N.º 5, pp. 382-385
Fernandes SR, Baldaia C, Marques HP, Tortosa F, Ramalho F. Intrahepatic 
clear cell cholangiocarcinoma - An uncommon histologic subtype: case report 




Correspondence: Samuel R. Fernandes. Department of Gastroenterology and 
Hepatology. Hospital de Santa Maria. Centro Hospitalar Lisboa Norte. Av. 
Prof. Egas Moniz. 1649-035 Lisbon, Portugal
e-mail: Samuelrmfernandes@gmail.com
Author contributions: Samuel Raimundo Fernandes is the corresponding 
author. Preparation and review of the manuscript: Cilénia Baldaia and Hugo 
Pinto Marques. Analysis of anatomopathologic specimens and review of the 
manuscript: Francisco Tortosa. Critical review of the manuscript: Fernando 
Ramalho.
CASE REPORT
Intrahepatic clear cell cholangiocarcinoma - An uncommon histologic subtype: 
case report and literature review
Samuel Raimundo Fernandes1, Cilénia Baldaia1, Hugo Pinto Marques2, Francisco Tortosa3 and Fernando Ramalho1
1Department of Gastroenterology and Hepatology. Hospital de Santa Maria. Centro Hospitalar Lisboa Norte. Lisbon, Portugal. 2Department of Hepatobiliary 
Surgery. Hospital Curry Cabral. Centro Hospitalar Lisboa Central. Lisbon, Portugal. 3Department of Anatomic Pathology. Hospital de Santa Maria. Centro 
Hospitalar Lisboa Norte. Lisbon, Portugal
ABSTRACT
Clear-cell cholangiocarcinoma is a very uncommon variant of 
cholangiocarcinoma with a largely unknown natural history and 
prognosis. We report a case of a 51-year-old previously healthy 
woman presenting with a large liver nodule found on routine 
imaging. Needle biopsy of the lesion suggested a non-hepatocellular 
carcinoma. After extensive workup for other primary neoplasms, 
the patient underwent a partial hepatectomy. Histopathology 
was compatible with a moderately differentiated clear-cell 
cholangiocarcinoma. There was no evidence of liver disease in 
the remaining tissue. The patient underwent chemotherapy and 
remains in clinical remission after two years.
Key words: Liver nodule. Intrahepatic cholangiocarcinoma. 
Clear-cell carcinoma.
INTRODUCTION
Intrahepatic cholangiocarcinoma is the second most 
common primary hepatic neoplasm, and is responsible 
for up to 20% of all deaths related to hepatobiliary malig-
nancies (1). Most cholangiocarcinomas are adenocarcino-
mas histologically. Recently, a clear cell variant has been 
described. This histologic subtype is very rare, and so far 
only nine cases of intrahepatic clear cell cholangiocarci-
noma have been reported (2-8). This entity is character-
ized by cells with a clear cytoplasm and well-defined cell 
membrane, residing within a highly vascularized stroma. 
The clear cell changes are thought to result from accumu-
lated glycogen, phospholipids and neutral lipids, removed 
during conventional histological processing (3). Clear cell 
cholangiocarcinoma should be differentiated from other 
more common clear cell neoplasms such as those arising 
in the kidneys, lower urinary tract, skin, breast, ovaries 
and pancreas. In this report, we present a patient diag-
nosed with intrahepatic clear cell cholangiocarcinoma. The 
remaining liver showed no evidence of chronic disease or 
cirrhosis. We appraise the clinical and anatomopathologic 
findings, discuss treatment and prognosis, and review the 
available literature.
CASE REPORT
A 51-year-old black African woman was referred to 
our center for evaluation of a 9.5 cm solid mass in the 
right hepatic lobe found on an abdominal ultrasound 
during investigation for dyspeptic complaints. She denied 
any constitutional or other organ-related symptoms. Her 
medical history was significant for type 2 diabetes mel-
litus and systemic hypertension, both diagnosed seven 
years earlier. She was not overweight. She also denied 
alcohol, tobacco, and illicit drug use. There was no fam-
ily history of cancer or liver disease. On physical exam-
ination, the liver was tender and extended 2 cm below 
the right costal margin. She had no stigma of chronic liv-
er disease. Blood studies revealed normal aminotransfer-
ases and bilirubin with increased gamma-glutamyltrans-
peptidase (527 < 38 IU/L) and alkaline phosphatase (349 
< 129 IU/L). Tumor markers (α-fetoprotein, CA 19.9 
and CEA), auto-antibodies (anti-nuclear and anti-my-
tocondrial antibodies) and viral serologies (hepatitis B, 
C and HIV) were negative. Abdominal ultrasound and 
contrast enhanced CT-scan revealed a solid 9.5 x 9.8 cm 
lesion in the right hepatic lobe. The lesion showed het-
erogeneous enhancement after contrast administration. 
There was also potential invasion of one of the segmental 
branches of the portal vein. The case was discussed with 
our senior radiologist. As he believed there would be no 
further gain in diagnosis from performing a magnetic 
resonance imaging (MRI), ultrasound-guided fine needle 
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aspiration of the nodule was performed. The histologic 
examination showed multiple nests of cells with clear 
vacuolated cytoplasm arranged in a dense hyalinized 
stroma (Fig. 1 A and B). Immunohistochemical stain-
ing showed reactivity to vimentin, epithelial membrane 
antigen, cytokeratin (CK) 7, 8, 18, 19, 34betaE12 and 
polyclonal-carcinoembryonic antigen (Fig. 1C). There 
was no reaction to CD10, hepatocyte antigen, glypi-
can-3, thyroid transcription factor-1, chromogranin A, 
estrogen and progesterone receptors, CA-125, pS100 and 
CK 20. This immunohistochemical profile was incom-
patible with neuroendocrine and hepatocellular, thyroid, 
breast, ovary and kidney cancer, suggesting either a bil-
iary or pancreatic origin. In order to exclude another 
primary location of the neoplasm, we performed an 
extensive workup including upper and lower gastroin-
testinal endoscopy, capsule endoscopy, breast and vagi-
nal ultrasound, mammography and PET-scan. In light of 
the patient’s age and good performance status, she was 
referred for surgery. The lesion was subsequently resect-
ed via a right hepatectomy extended to segment IV and I 
with resection of the portal vein. The specimen measured 
11 x 10 x 9.5 cm and weighted 1,120 g. Macroscopically, 
the cut surface showed a solid yellowish-white tumor 
(Fig. 2). The tumor adhered to the gallbladder but there 
was a clear surgical margin. The remaining liver, hilum 
and supra-hepatic vessels showed no abnormalities. On 
histologic examination the tumor was composed of cells 
with a clear cytoplasm arranged in nests. Although there 
was evidence of microvascular invasion, there was a 
clear histological margin and no lymph node metastasis. 
The remaining liver showed no signs of chronic disease 
or cirrhosis. Immunohistochemical staining was posi-
tive for CK 7, focally for carcinoembryonic antigen, and 
negative for CK20, chromogranin, synaptophysin CD 10 
and ps100. According to these findings, the tumor was 
classified as a moderately differentiated clear cell chol-
angiocarcinoma. The patient was referred for adjuvant 
chemotherapy with gemcitabine. After two years of fol-
low-up, the patient remains free from disease recurrence.
Fig. 1. Pathological findings (hematoxylin-eosin). Infiltration by cells with a clear cytoplasm with irregular nuclei arranged around a vascularized stroma. 
A. x20. B. x40. C. Immunohistochemistry showing positivity for cytokeratin 7.
DISCUSSION
Clear cell changes have been uncommonly reported in 
patients with intrahepatic cholangiocarcinoma (Table I). 
Due to the paucity of data available, pathogenesis, risk 
factors and prognosis remain largely unknown. Like in 
other cholangiocarcinomas, an association with chronic 
liver disease has been suggested. This was the case in the 
report by Toriyama, where the patient was chronically 
infected with hepatitis B (2), and in the paper by Falta 
(5) where, like in our patient, type 2 diabetes mellitus and 
systemic hypertension were present, suggesting a potential 
link with metabolic syndrome and non-alcoholic steato-
hepatitis. Distinguishing clear cell cholangiocarcinoma 
from other benign and malignant lesions may be difficult. 
Considering the patient’s age and gender, benign lesions 
including adenoma and focal nodular hyperplasia should 
be excluded. In addition, our patient had diabetes, a known 
risk factor for hepatocellular carcinoma. As the patient’s 
radiologic findings were inconclusive, we performed a fine 
Fig. 2. 
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needle aspiration of the lesion which suggested a biliary or 
pancreatic origin, allowing us to exclude other more com-
mon lesions. However, as is common in this procedure, the 
limited sample could not provide a definite diagnosis or 
exclude secondary metastasis from other organs. Immuno-
histochemistry may play an important role in this setting. 
Positive expression of CK7 and the absence of CK20 are 
compatible with cholangiocarcinoma. On the other hand, 
hepatocellular carcinoma usually expresses both hepato-
cyte antigen and α-fetoprotein (9). Nevertheless, in many 
cases a definite diagnosis can only be performed post-sur-
gically. Intrahepatic cholangiocarcinoma is an aggressive 
malignancy with five-year survival rates ranging between 
0 and 43% (1). Chemotherapy and radiotherapy have until 
now shown little to no benefit in increasing survival, and 
surgical resection remains the only potentially curative 
therapy (10). Unfortunately, most cases are diagnosed 
at an advanced stage, when complete resection is hard-
ly ever possible. Advanced tumor stage, positive margins 
after resection, and the presence of microvascular inva-
sion or intrahepatic satellite lesions have been identified 
as unfavorable predictors of outcome (10). Nevertheless, 
some authors have suggested a more favorable prognosis 
in patients with clear cell changes. In the reports published 
to date, and including our own, nearly all patients were 
alive at one year, and most survived beyond three years. 
Once again, the number of patients and follow-up time 
were insufficient.
The present case seemed of great interest due to the rarity 
of the situation, age at presentation, and absence of other 
significant risk factors. We emphasize the utility of immu-
nochemistry in reaching the final diagnosis. In conclusion, 
clear cell cholangiocarcinoma is a rare histologic variant. 
Until more data is available, we can only speculate about the 
risk factors, natural history and prognosis of this neoplasm.
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Table I. Reported cases on intrahepatic clear cell cholangiocarcinoma
Year Age (yr)/sex Size (cm) Risk factors CLD Treatment Prognosis
2010 (2) 56/M 2.2, RLL Hepatitis B CLD, no cirrhosis Surgery + adjuvant chemotherapy Alive at 7 m
2007 (3) 51/M 9, LLL N/A N/A N/A Dead at 3 yr
2007 (3) 60/F 4.5, RLL N/A N/A N/A Alive at 1 yr
2007 (3) 58/F 2.3, RLL N/A N/A N/A Alive, N/A
1998 (4) 72/M 15, LLL Heavy alcohol CLD, no cirrhosis Surgery Alive at 30 m
1999 (5) 50/M 1.5, RLL Diabetes No cirrhosis Surgery Alive at 12 m
1998 (6) 64/F 12, N/A N/A N/A Surgery N/A
1998 (7) 62/M 5, RLL Smoke, moderate alcohol CLD, no cirrhosis no treatment Dead at 15 m
2001 (8) 64/M 6, RLL N/A N/A N/A Alive at 3 yr
Present case 51/F 9.5, RLL Diabetes, hypertension No cirrhosis Surgery + adjuvant chemotherapy Alive at 2 yr
M: Male; F: Female; yr: Year; m: Month; N/A: Information not available; RLL: Right liver lobe; LLL: Left liver lobe; CLD: Chronic liver disease.
